NCT00303992View on ClinicalTrials.gov

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

November 16, 2006

Study Completion Date

January 31, 2013

Conditions
Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

DRUG

irinotecan hydrochloride

Trial Locations (1)

94115-1710

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT00303992 - Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter